04.03.2011
The Annual Report 2010 for NeuroSearch A/S (NEUR) will be released on Thursday
10 March 2011.
NeuroSearch will host a conference call on the same day at 10.30 am local time (09.30 am UK time, 04.30 am New York time). Participating in the call will be CEO Patrik Dahlen and EVP & CFO René Schneider.
The conference call will be conducted in English and the dial-in numbers are:
UK: +44 207 509 5139, the US: +1 718 354 1226, DK +45 3271 4767.
The conference call can also be accessed on the company's website www.neurosearch.com.
The corresponding Power Point presentation will be available at the company's website just before the teleconference.
Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700
About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a pipeline of speciality CNS drugs, including the lead product Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil® through an in-house marketing and sales organisation.
NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and monoamine transporters. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of private companies in the Life Science industry.
